Literature DB >> 15807862

CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.

B Vander Cruyssen1, H Peeters, I E A Hoffman, D Laukens, P Coucke, D Marichal, C Cuvelier, E Remaut, E M Veys, H Mielants, M De Vos, F De Keyser.   

Abstract

Carriage of CARD15 gene polymorphisms and the serological marker anti-Saccharomyces cerevisiae antibodies (ASCA) are two markers for Crohn's disease (CD). Similar phenotypes have been associated with both markers. In the present study we analysed whether both markers were associated with each other and, if so, whether this association could be explained by a direct link or by an indirect association with those phenotypes. Therefore, we included 156 consecutive Caucasian CD patients and assessed the prevalence of the three common single nucleotide polymorphisms in the CARD15 gene. Serum samples were analysed for IgA and IgG ASCA by ELISA. CD patients with CARD15 polymorphisms were more frequently ASCA positive (OR 2.7 (1.4-5.2); P = 0.002) and had higher titres for ASCA IgA (P = 0.005) and ASCA IgG (P < 0.001) compared to patients carrying the wild type polymorphisms. Multivariate analysis demonstrated that this association was independent from ileal disease, penetrating disease and stricturing disease, the need for resective bowel surgery, familial cases, smoking habits and early age at onset. Homozygotes or compound heterozygotes for CARD15 polymorphisms had significantly more frequent ASCA positivity compared to single heterozygotes (OR 9.1 (1.1-74.2), P(c) (corrected P-value) = 0.030). These data indicate that there is a significant association between the carriage of CARD15 polymorphisms and ASCA, independent of the described phenotypes. Moreover, ASCA positivity is more frequent in CD patients carrying 2 CARD15 polymorphisms compared to single heterozygotes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15807862      PMCID: PMC1809370          DOI: 10.1111/j.1365-2249.2005.02759.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.

Authors:  C L Sutton; H Yang; Z Li; J I Rotter; S R Targan; J Braun
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

2.  Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

Authors:  S Vermeire; M Peeters; R Vlietinck; S Joossens; E Den Hond; V Bulteel; X Bossuyt; B Geypens; P Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2001-02       Impact factor: 5.325

3.  Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease.

Authors:  S Vermeire; S Joossens; M Peeters; F Monsuur; G Marien; X Bossuyt; P Groenen; R Vlietinck; P Rutgeerts
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

4.  Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease.

Authors:  E Lindberg; K E Magnusson; C Tysk; G Järnerot
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

5.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  J F Quinton; B Sendid; D Reumaux; P Duthilleul; A Cortot; B Grandbastien; G Charrier; S R Targan; J F Colombel; D Poulain
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

6.  Serological markers and HLA genes among healthy first-degree relatives of patients with coeliac disease.

Authors:  M Mäki; K Holm; V Lipsanen; O Hällström; M Viander; P Collin; E Savilahti; S Koskimies
Journal:  Lancet       Date:  1991-11-30       Impact factor: 79.321

7.  Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study.

Authors:  F Seibold; O Stich; R Hufnagl; S Kamil; M Scheurlen
Journal:  Scand J Gastroenterol       Date:  2001-02       Impact factor: 2.423

8.  Specific antibody response to oligomannosidic epitopes in Crohn's disease.

Authors:  B Sendid; J F Colombel; P M Jacquinot; C Faille; J Fruit; A Cortot; D Lucidarme; D Camus; D Poulain
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

9.  HLA-associated heterogeneity of the humoral response to islet antigens in insulin-dependent diabetes.

Authors:  M Delamaire; J Timsit; S Caillat-Zucman; D Maugendre; H Roussely; G Semana; A M Yamamoto; P van Endert; C Boitard; B Genetet
Journal:  J Autoimmun       Date:  1995-10       Impact factor: 7.094

10.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease.

Authors:  J Main; H McKenzie; G R Yeaman; M A Kerr; D Robson; C R Pennington; D Parratt
Journal:  BMJ       Date:  1988-10-29
View more
  7 in total

1.  Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.

Authors:  Zhaoxia Zhang; Chen Li; Xinmei Zhao; Chaolan Lv; Qiong He; Shan Lei; Yandong Guo; Fachao Zhi
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

Review 2.  A tug-of-war between the host and the pathogen generates strategic hotspots for the development of novel therapeutic interventions against infectious diseases.

Authors:  Aarti Rana; Mushtaq Ahmed; Abdur Rub; Yusuf Akhter
Journal:  Virulence       Date:  2015-06-24       Impact factor: 5.882

3.  Inflammatory bowel disease serology in Asia and the West.

Authors:  Lani Prideaux; Michael A Kamm; Peter De Cruz; Daniel R van Langenberg; Siew C Ng; Iris Dotan
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

4.  Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease.

Authors:  Grace Gathungu; Mi-Ok Kim; John P Ferguson; Yashoda Sharma; Wei Zhang; Sok Meng E Ng; Erin Bonkowski; Kaida Ning; Lisa A Simms; Anthony R Croft; Joanne M Stempak; Nicole Walker; Ning Huang; Yang Xiao; Mark S Silverberg; Bruce Trapnell; Judy H Cho; Graham L Radford-Smith; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

5.  Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease.

Authors:  Liesbet Henckaerts; Marie Pierik; Marie Joossens; Marc Ferrante; Paul Rutgeerts; Séverine Vermeire
Journal:  Gut       Date:  2007-06-26       Impact factor: 23.059

Review 6.  How expensive is inflammatory bowel disease? A critical analysis.

Authors:  Selwyn Odes
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

7.  Diagnostic utility of serological biomarkers in patients with Crohn's disease: A case-control study.

Authors:  Fang Yao; Yihong Fan; Bin Lv; Conghua Ji; Li Xu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.